AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Journal of Neurorestoratology Article
Article Link
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Case Report | Open Access

Repetitive transcranial magnetic stimulation alleviates depression in a young patient with CADASIL: A case report

Mengru Qia,1, Mengke Bana,1, Zhaoyang Lua, Shuwen Caoa, Ranran Yanga, Ping Zhanga( ), Jinggui Songb( )
Department of Neurology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453000, Henan, China
Department of Neurology, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang 453000, Henan, China

1 They contributed equally to this work and should be considered co-first authors.

Show Author Information

Abstract

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a relatively common inherited arterial smooth muscle cell disease. The genetic defect is localized to the notch homolog protein 3 (NOTCH3) gene on chromosome 19q12 and is due to a missense variant in NOTCH3. The main clinical manifestations are transient ischemic attacks and repeated stroke, with cognitive impairments leading to dementia, migraine with aura, and mental/emotional disorders. To date, there is no specific therapeutic option, with only symptomatic supportive treatment for the symptoms of acute stroke, migraine, dementia, and mental abnormalities. Here, we provide a case report of a Chinese patient with CADASIL and a mutation in exon 4 of the NOTCH3 gene (p.Arg133Cys). The patient mainly exhibited recurrent cerebral infarction and affective disorder. Antidepressant treatment combined with repetitive transcranial magnetic stimulation significantly improved the depressive symptoms of the patient.

Keywords

Affective disorderIschemic strokeCADASILrTMS

References

1

Uyama E, Tokunaga M, Suenaga A, et al. Arg133Cys mutation of Notch3 in two unrelated Japanese families with CADASIL. Intern Med. 2000;39(9):732–737. https://doi.org/10.2169/internalmedicine.39.732.
Crossref Google Scholar
2

Dichgans M, Mayer M, Uttner I, et al. The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol. 1998;44(5):731–739. https://doi.org/10.1002/ana.410440506.
Crossref Google Scholar
3

Desmond DW, Moroney JT, Lynch T, et al. The natural history of CADASIL: a pooled analysis of previously published cases. Stroke. 1999;30(6):1230–1233. https://doi.org/10.1161/01.str.30.6.1230.
Crossref Google Scholar
4

Bousser M, Tournier-Lasserve E. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: from stroke to vessel wall physiology. J Neurol Neurosurg Psychiatry. 2001;70(3):285–287. https://doi.org/10.1136/jnnp.70.3.285.
Crossref Google Scholar
5

Singhal S, Bevan S, Barrick T, et al. The influence of genetic and cardiovascular risk factors on the CADASIL phenotype. Brain. 2004;127(Pt 9):2031–2038. https://doi.org/10.1093/brain/awh223.
Crossref Google Scholar
6

Opherk C, Peters N, Herzog J, et al. Long-term prognosis and causes of death in CADASIL: a retrospective study in 411 patients. Brain. 2004;127(Pt 11):2533–2539. https://doi.org/10.1093/brain/awh282.
Crossref Google Scholar
7

Chabriat H, Joutel A, Dichgans M, et al. Cadasil. Lancet Neurol. 2009;8(7):643–653. https://doi.org/10.1016/S1474-4422(09)70127-9.
Crossref
8

Dichgans M. Cognition in CADASIL. Stroke. 2009;40(3 suppl l):S45–S47. https://doi.org/10.1161/STROKEAHA.108.534412.
Crossref Google Scholar
9

Noh SM, Chung SJ, Kim KK, et al. Emotional disturbance in CADASIL: its impact on quality of life and caregiver burden. Cerebrovasc Dis. 2014;37(3):188–194. https://doi.org/10.1159/000357798.
Crossref Google Scholar
10

Park S, Park B, Koh MK, et al. Case report: bipolar disorder as the first manifestation of CADASIL. BMC Psychiatr. 2014;14:175. https://doi.org/10.1186/1471-244X-14-175.
Crossref Google Scholar
11

Chabriat H, Bousser MG. Neuropsychiatric manifestations in CADASIL. Dialogues Clin Neurosci. 2007;9(2):199–208. https://doi.org/10.31887/DCNS.2007.9.2/hchabriat.
Crossref Google Scholar
12

Di Donato I, Bianchi S, De Stefano N, et al. Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) as a model of small vessel disease: update on clinical, diagnostic, and management aspects. BMC Med. 2017;15(1):41. https://doi.org/10.1186/s12916-017-0778-8.
Crossref Google Scholar
13

Singhal S, Rich P, Markus HS. The spatial distribution of MR imaging abnormalities in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy and their relationship to age and clinical features. AJNR Am J Neuroradiol. 2005;26(10):2481–2487. pmid: 16286388.
Google Scholar
14

Auer DP, Pütz B, Gössl C, et al. Differential lesion patterns in CADASIL and sporadic subcortical arteriosclerotic encephalopathy: MR imaging study with statistical parametric group comparison. Radiology. 2001;218(2):443–451. https://doi.org/10.1148/radiology.218.2.r01fe24443.
Crossref Google Scholar
15

O'Sullivan M, Jarosz JM, Martin RJ, et al. MRI hyperintensities of the temporal lobe and external capsule in patients with CADASIL. Neurology. 2001;56(5):628–634. https://doi.org/10.1212/wnl.56.5.628.
Crossref Google Scholar
16

Lee YC, Liu CS, Chang MH, et al. Population-specific spectrum of NOTCH3 mutations, MRI features and founder effect of CADASIL in Chinese. J Neurol. 2009;256(2):249–255. https://doi.org/10.1007/s00415-009-0091-3.
Crossref Google Scholar
17

Abramycheva N, Stepanova M, Kalashnikova L, et al. New mutations in the Notch3 gene in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL). J Neurol Sci. 2015;349(1–2):196–201. https://doi.org/10.1016/j.jns.2015.01.018.
Crossref Google Scholar
18

Ayrignac X, Carra-Dalliere C, Menjot de Champfleur N, et al. Adult-onset genetic leukoencephalopathies: a MRI pattern-based approach in a comprehensive study of 154 patients. Brain. 2015;138(Pt 2):284–292. https://doi.org/10.1093/brain/awu353.
Crossref Google Scholar
19

Algahtani H, Shirah B, Alharbi SY, et al. A novel heterozygous variant in exon 19 of NOTCH3 in a Saudi family with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. J Stroke Cerebrovasc Dis. 2020;29(7):104832. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104832.
Crossref Google Scholar
20

Pantoni L, Pescini F, Nannucci S, et al. Comparison of clinical, familial, and MRI features of CADASIL and NOTCH3-negative patients. Neurology. 2010;74(1):57–63. https://doi.org/10.1212/WNL.0b013e3181c7da7c.
Crossref Google Scholar
21

van den Boom R, Lesnik Oberstein SA, Ferrari MD, et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: MR imaging findings at different ages—3rd-6th decades. Radiology. 2003;229(3):683–690. https://doi.org/10.1148/radiol.2293021354.
Crossref Google Scholar
22

Schneider LS. Does donepezil improve executive function in patients with CADASIL? Lancet Neurol. 2008;7(4):287–289. https://doi.org/10.1016/S1474-4422(08)70047-4.
Crossref Google Scholar
23

Shin D, Oh YH, Eom CS, et al. Use of selective serotonin reuptake inhibitors and risk of stroke: a systematic review and meta-analysis. J Neurol. 2014;261(4):686–695. https://doi.org/10.1007/s00415-014-7251-9.
Crossref Google Scholar
24

del Río-Espínola A, Mendióroz M, Domingues-Montanari S, et al. CADASIL management or what to do when there is little one can do. Expert Rev Neurother. 2009;9(2):197–210. https://doi.org/10.1586/14737175.9.2.197.
Crossref Google Scholar
25

Kwok CS, Shoamanesh A, Copley HC, et al. Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke: pooled analysis of randomized trials. Stroke. 2015;46(4):1014–1023. https://doi.org/10.1161/STROKEAHA.114.008422.
Crossref Google Scholar
26

Kim BJ, Kwon SU, Park JH, et al. Cilostazol versus aspirin in ischemic stroke patients with high-risk cerebral hemorrhage: subgroup analysis of the PICASSO trial. Stroke. 2020;51(3):931–937. https://doi.org/10.1161/STROKEAHA.119.023855.
Crossref Google Scholar
27

Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010;9(10):959–968. https://doi.org/10.1016/S1474-4422(10)70198-8.
Crossref Google Scholar
28

Rizzo M, Corrado E, Patti AM, et al. Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? Expet Opin Pharmacother. 2011;12(4):647–655. https://doi.org/10.1517/14656566.2011.557359.
Crossref Google Scholar
29

Kwon SU, Cho YJ, Koo JS, et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke. 2005;36(4):782–786. https://doi.org/10.1161/01.STR.0000157667.06542.b7.
Crossref Google Scholar
30

Law ZK, Tan HJ, Chin SP, et al. The effects of intravenous infusion of autologous mesenchymal stromal cells in patients with subacute middle cerebral artery infarct: a phase 2 randomized controlled trial on safety, tolerability and efficacy. Cytotherapy. 2021;23(9):833–840. https://doi.org/10.1016/j.jcyt.2021.03.005.
Crossref Google Scholar
31

Bornstein NM, Saver JL, Diener HC, et al. An injectable implant to stimulate the sphenopalatine ganglion for treatment of acute ischaemic stroke up to 24 h from onset (ImpACT-24B): an international, randomised, double-blind, sham-controlled, pivotal trial. Lancet. 2019;394(10194):219–229. https://doi.org/10.1016/S0140-6736(19)31192-4.
Crossref Google Scholar
32

Chen LT, Peng JJ, Huang XL, et al. Research on the electroacupuncture promoting learning and memory of rats with cerebral hypoperfusion through NGF/TrkA signal pathway (in Chinese). Chin J Rehabil Med. 2020;35(2):129–134, 1001-1242(2020)-02-0129-06.
Google Scholar
Journal of Neurorestoratology
Volume 12 Issue 1,
March 2024
Article number: 100093
DOI: 10.1016/j.jnrt.2023.100093
Cite this article:
Qi M, Ban M, Lu Z, et al. Repetitive transcranial magnetic stimulation alleviates depression in a young patient with CADASIL: A case report. Journal of Neurorestoratology, 2024, 12(1): 100093. https://doi.org/10.1016/j.jnrt.2023.100093

230

Views

0

Crossref

0

Web of Science

0

Scopus

Altmetrics
Received: 15 February 2023
Revised: 14 November 2023
Accepted: 05 December 2023
Published: 22 December 2023
© 2023 The Authors.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Return